Given the "addiction" of many tumors to mutant RAS for their survival, there has been renewed interest in developing new ways to inhibit RAS in cancer.
John P. O’Bryan, PhD
Advertisement
Articles by John P. O’Bryan, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5